Buy Increlex in India — Price & Availability

What is Increlex used for?

Increlex (mecasermin) is a recombinant form of human insulin-like growth factor-1 (IGF-1), the key hormone through which growth hormone promotes childhood growth. In children who cannot make or respond to enough IGF-1, replacing it directly supports statural growth.

It is approved for:

• Growth failure in paediatric patients 2 years of age and older with severe primary IGF-1 deficiency (severe primary IGFD), or with growth hormone (GH) gene deletion who have developed neutralising antibodies to GH.

Severe primary IGFD is defined by a height standard deviation score ≤ −3.0 together with a basal IGF-1 standard deviation score ≤ −3.0 and normal or elevated growth hormone. Increlex is not a substitute for growth hormone in approved GH indications, and it is not for secondary forms of IGF-1 deficiency such as GH deficiency, malnutrition, or hypothyroidism. Treatment should be supervised by a physician experienced in managing children with growth disorders.

Recommended dosage:
Increlex is given by subcutaneous injection, and the dose is individualised by body weight:

• Recommended starting dose: 0.04 mg/kg to 0.08 mg/kg twice daily.
  If well tolerated for at least one week, the dose may be increased by 0.04 mg/kg per dose, up to a maximum of 0.12 mg/kg twice daily.

Increlex should be given shortly before or after a meal or snack, because it can cause low blood sugar (hypoglycaemia); if the child cannot eat, the dose should be skipped. Injection sites are rotated to avoid lipohypertrophy. The treating specialist always determines the exact dose and any adjustments.

• Hypoglycemia: Increlex may cause severe low blood sugar, including seizures. To reduce this risk, it should be given shortly before or after a meal or snack, exactly as directed by the treating physician.
• Hypersensitivity and Allergic Reactions: Serious allergic reactions, including anaphylaxis, have been reported. Stop treatment immediately and seek urgent medical attention if swelling, difficulty breathing, or any severe allergic symptoms occur.
• Intracranial Hypertension: This medicine may increase pressure inside the skull. Regular eye examinations are recommended before and during treatment to detect early signs and help prevent potential vision-related complications.
• Lymphoid Tissue Hypertrophy: Treatment with this drug may cause enlargement of the tonsils or adenoids. Regular medical check-ups can help identify complications such as snoring, breathing difficulties, or recurrent ear infections.
• Slipped Capital Femoral Epiphysis (SCFE): Children who develop hip pain, knee pain, or begin limping during treatment should be evaluated promptly, as these symptoms may indicate a serious hip condition requiring medical attention.
• Progression of Scoliosis: Children with scoliosis should be monitored regularly during this treatment, as periods of rapid growth may increase the progression of spinal curvature in some patients.
• Malignant Neoplasia: Rare cases of cancer have been reported during Increlex treatment. Therapy should be stopped immediately if cancer is suspected, and the patient should receive prompt specialist medical evaluation.
• Benzyl Alcohol Warning: This medicinal product contains benzyl alcohol, which may cause serious or fatal reactions in newborns and infants. Therefore, its use is not recommended in this age group.

Common side effects:
Common side effects include hypoglycaemia, injection-site reactions and lipohypertrophy, tonsillar/adenoid enlargement, headache, and ear-related symptoms. This is not a complete list — refer to the full prescribing information and your doctor.

Patients in India can legally access Increlex through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Increlex is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Increlex:

• A valid prescription from a qualified specialist (paediatric endocrinologist)
• The patient’s diagnostic reports, including IGF-1 level and height data supporting the diagnosis
• Government-issued patient ID proof
• An import permit, where applicable

Because Increlex is not sold on the open market in India, there is no fixed MRP. The Increlex cost in India depends on a few factors at the time of import:

• The number of vials required, which is based on the child’s body weight, the prescribed twice-daily dose, and the treatment duration.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Increlex cost, logistics, and delivery timeline once a valid prescription is shared. Request your Increlex quote →

Increlex is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.

Indian Pharma Network sources Increlex from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Increlex vials require cold-chain handling: stored refrigerated at 2 °C–8 °C and never frozen. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Increlex available in India?

Increlex (mecasermin injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Increlex is not commercially marketed in India.

However, patients in India can legally access Increlex through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Increlex in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Increlex price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Increlex can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:

Increlex first received US FDA approval in 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralising antibodies to GH. It is also approved in the European Union and other markets. As of the current publicly available information, Increlex is not commercially marketed in India, which is why the Named Patient route is used.